Biogen Inc (BSP:BIIB34)
R$ 169.49 1.36 (0.81%) Market Cap: 149.37 Bil Enterprise Value: 178.06 Bil PE Ratio: 15.80 PB Ratio: 1.56 GF Score: 75/100

Biogen Inc to Present at the American Neurological Association Virtual Meeting Transcript

Oct 17, 2021 / 08:20 PM GMT


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BIIB.OQ - Biogen Inc
Biogen Inc to Present at the American Neurological Association Virtual Meeting
Oct 17, 2021 / 08:20PM GMT

=====================
Conference Call Participants
=====================
* Timothy Miller

=====================
Presentation
--------------------------------------------------------------------------------
Timothy Miller, [1]
--------------------------------------------------------------------------------
My name is Tim Miller. And on behalf of Merit Cudkowicz and the VALOR Working Group, I am delighted to present today results from the Phase III VALOR study and its open-label extension evaluating the clinical efficacy and safety of tofersen in adults with ALS and confirmed SOD1 mutation.

This study was sponsored by Biogen and uses antisense oligonucleotides developed by Ionis Pharmaceuticals, so some relevant disclosures. I serve on an advisory board and received clinical support for -- from Biogen and have a licensing agreement with and consulting for Ionis Pharmaceuticals, and you
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot